Current status and future prospective of focal therapy for localized prostate cancer: development of multiparametric MRI, MRI-TRUS fusion image-guided biopsy, and treatment modalities
- 10 February 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 25 (4), 509-520
- https://doi.org/10.1007/s10147-020-01627-8
Abstract
Multiparametric magnetic resonance imaging (mpMRI) has been increasingly used to diagnose clinically significant prostate cancer (csPC) because of its usefulness in combination with anatomic and functional data. MRI-targeted biopsy, such as MRI-transrectal ultrasound (TRUS) fusion image-guided prostate biopsy, has high accuracy in the detection and localization of csPC. This novel diagnostic technique contributes to the development of tailor-made medicine as focal therapy, which cures the csPC while preserving the anatomical structures related to urinary and sexual function. In the early days of focal therapy, TRUS-guided systematic biopsy was used for patient selection, and treatment was performed for patients with low-risk PC. With the introduction of mpMRI and mapping biopsy, the treatment range is now determined based on individualized cancer localization. In recent prospective studies, 87.4% of treated patients had intermediate- and high-risk PC. However, focal therapy has two main limitations. First, a randomized controlled trial would be difficult to design because of the differences in pathological features between patients undergoing focal therapy and radical treatment. Therefore, pair-matched studies and/or historical controlled studies have been performed to compare focal therapy and radical treatment. Second, no long-term (≥ 10-year) follow-up study has been performed. However, recent prospective studies have encouraged the use of focal therapy as a treatment strategy for localized PC because it contributes to high preservation of continence and erectile function.Keywords
Funding Information
- Takeda Science Foundation
This publication has 63 references indexed in Scilit:
- Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development studyThe Lancet Oncology, 2012
- ESUR prostate MR guidelines 2012European Radiology, 2012
- Permanent Interstitial Low-Dose-Rate Brachytherapy for Patients with Localised Prostate Cancer: A Systematic Review of Randomised and Nonrandomised Controlled Clinical TrialsEuropean Urology, 2011
- Primary full‐gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD RegistryBJU International, 2011
- Focal Therapy for Localized Prostate Cancer: A Phase I/II TrialJournal of Urology, 2011
- Is Apparent Diffusion Coefficient Associated with Clinical Risk Scores for Prostate Cancers that Are Visible on 3-T MR Images?Radiology, 2011
- Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imagingBJU International, 2010
- Quality of life following high‐intensity focused ultrasound for the treatment of localized prostate cancer: A prospective studyInternational Journal of Urology, 2010
- Focal Therapy with High-intensity-focused Ultrasound in the Treatment of Localized Prostate CancerJapanese Journal of Clinical Oncology, 2008
- Focal Prostate Cryoablation: Initial Results Show Cancer Control and Potency PreservationJournal of Endourology, 2006